Addictive Potential: Unkown
Emergency Room Visits Yearly: Unknown
Mandatory Minimum Sentence: Unknown
Mechanism of Action: Cannabinoid receptor inverse agonist
Rimonabant (also known as SR141716; trade names Acomplia, Bethin, Monaslim, Remonabent, Riobant, Slimona, Rimoslim, Zimulti, and Riomont) is an anorectic antiobesity drug. It is an inverse agonist for the cannabinoid receptor CB1. Its main effect is reduction in appetite. Rimonabant blocks the psychoactive and some of the cardiovascular effects of Δ9-tetrahydrocannabinol (THC) in humans without affecting the pharmacokinetics.
Rimonabant as a Treatment for Addictions. Rimonabant reduced resumption of cocaine-seeking responses triggered by two of the three most common triggers of relapse in humans, priming and cues. It may also reduce ethanol- and opiate-seeking behavior.
Side Effects and Adverse Reactions:
Shortly after market introduction, press reports and independent studies suggested side effects occurred more intensely and more commonly than shown by the manufacturer in their clinical studies. Resulting from drug actions at CB1 receptors in the brain, reports of severe depression and suicidal thoughts are frequent. As CB1 receptors are fairly ubiquitous throughout the central nervous system, it is not currently understood where exactly the inverse agonist is acting to cause these side-effects.
On 15 June 2007, BBC News reported a committee advising the U.S. FDA had voted not to recommend the drug’s approval because of concerns over suicidality, depression, and other related side effects associated with use of the drug.